Condition: Non-small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC) · Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: Revolution Medicines, Inc.
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
This description comes directly from the study's public registry record.
Revolution Medicines, Inc. · 1-844-273-8633 · medinfo@revmed.com
Always discuss trial participation with your own doctor first.
| UC Irvine/Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| UCLA | Santa Monica, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Piedmont Healthcare | Atlanta, Georgia, United States | Recruiting |
| Mary Bird Perkins Cancer Center | Baton Rouge, Louisiana, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Perlmutter Cancer Center at NYU Langone Health | New York, New York, United States | Recruiting |
| Memorial Sloan-Kettering Cancer Center | New York, New York, United States | Recruiting |
| Columbia University | New York, New York, United States | Recruiting |
| Christ Hospital Cancer Center | Cincinnati, Ohio, United States | Recruiting |
| Taylor Cancer Research Center | Maumee, Ohio, United States | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05379985